Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, U.S.A. and U.K.

Baron, Elma D.; Barzilai, David A.; Johnston, Graham A.R.; Kawashima, Makoto; Takigawa, Masaharu; Nakagawa, Hidemi; Graham‐Brown, R.A.C.; Stevens, Seth R.

doi:10.1046/j.1365-2133.2002.04895.x

Cited by 25 publications

(19 citation statements)

References 24 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the respondents (60-100%) in the Asian study prescribed both sedating and nonsedating antihistamines, but some physicians from Indonesia (21%), the Philippines (21%) and Vietnam (31%) only prescribed Review Allergies in Asia: differences in prevalence & management compared with Western populations nonsedating antihistamines [74]. The use of alternative remedies for AD is significantly more common in Japan than in the USA and the UK [75].…”

Section: Management Of Asthma Allergic Rhinitis and Ad In Asiamentioning

confidence: 99%

“…However, respondents from the Philippines and Vietnam only used steroids and antibiotics in severe AD cases [74]. A comparative study showed that physicians from the USA and the UK were signi ficantly more aggressive in prescribing systemic medications such as steroids, antibiotics and immunosuppressants compared with those in Japan [75]. Oral antihistamines have only a limited effect on itching and it is mainly the older sedating antihistamines that have been shown to be effective.…”

Section: Management Of Asthma Allergic Rhinitis and Ad In Asiamentioning

confidence: 99%

See 1 more Smart Citation

Allergies in Asia: differences in prevalence and management compared with Western populations

Gerez¹,

Lee²,

Bever³

2010

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

There is wide variability in the epidemiology and management of childhood asthma and related atopic diseases globally. Urbanized, affluent Western countries tend to have a higher prevalence of these diseases compared with Asian nations. However, recent studies have shown that the prevalence in Asia is increasing, although the rate of increase has slowed in the more developed Asian cities. Some possible causes for these differences are socioeconomic status, degree of urbanization, rates of infection, healthcare practices and genetic factors. Importantly, there are significant differences in the way asthma and allergic diseases are managed within Asia. This is of great concern because of the health implications, as these diseases are some of the most common chronic conditions that affect both adults and children. This review compares the differences in prevalence and management between Asia and the West, and discusses some of the possible reasons behind these variations.

show abstract

Section: Management Of Asthma Allergic Rhinitis and Ad In Asiamentioning

confidence: 99%

Section: Management Of Asthma Allergic Rhinitis and Ad In Asiamentioning

confidence: 99%

Allergies in Asia: differences in prevalence and management compared with Western populations

Gerez¹,

Lee²,

Bever³

2010

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Atopic dermatitis (AD) is a chronic inflammatory disorder of the skin that represents a major public health problem worldwide, affecting approximately 5–20% of the pediatric population 1,2 . Although the management of AD may vary in different countries, topical corticosteroids have been the most commonly used anti‐inflammatory treatment 3,4 . Because their prolonged use is limited by local and systemic side‐effects, 5 therapeutic alternatives are highly desirable for the long‐term management of AD.…”

Section: Introductionmentioning

confidence: 99%

Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis

Eichenfield

Matsunaga³

et al. 2007

The Journal of Dermatology

View full text Add to dashboard Cite

Pimecrolimus cream 1% is a topical calcineurin inhibitor for the treatment of atopic dermatitis. Minimal systemic exposure to pimecrolimus has been previously observed in Caucasian pediatric patients treated with the cream twice daily for up to 1 year. The objective of this open-label, non-comparative, multicenter study was to assess the systemic exposure, tolerability and efficacy of pimecrolimus cream 1% when used twice daily for 3 weeks in pediatric patients of Japanese background. The patient cohort consisted of 17 Japanese infants and children (age range, 3.6 months to 11.6 years) with atopic dermatitis of at least mild severity affecting >or=10% of the total body surface area (range, 10-48%). Pimecrolimus cream 1% was applied twice daily for 3 weeks. Blood levels of pimecrolimus were determined on days 1, 10 and 22. Safety and tolerability were evaluated by monitoring adverse events, laboratory parameters, physical condition and vital signs. Efficacy parameters included the Eczema Area and Severity Index, the Investigators' Global Assessment and the pruritus score. The median exposure to pimecrolimus cream 1% was 22 treatment days (range, 9-29 treatment days). Pimecrolimus blood concentrations were <0.5 ng/mL in 94% of samples on day 1, in 93% of samples on day 10 and in 100% of samples on day 22, with no indication of an increase with increasing body surface area treated (up to 48% of the total body surface area). No drug-related systemic adverse events or serious adverse events were reported. Treatment was effective according to all efficacy parameters. The findings of this study indicate that the use of pimecrolimus cream 1% results in minimal systemic absorption of the active ingredient in pediatric patients of Japanese background with extensive disease.

show abstract

“…3′ For the third line, in addition to guideline 3, above, anti-mycotic agents are suggested for possible mycosis in the intestine, ultraviolet therapy, psychotherapy and anti-allergic treatment for metals are recommended (18,19). Systemic use of immunosuppressive agents is not highly recommended in Japan, and topical use of tacrolimus by professional dermatologists with informed consent has been recommended (20)…”

Section: Discussionmentioning

confidence: 99%

An Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and Discussion

Kobayashi

Takahashi²,

Mizuno

et al. 2004

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

In the first part of this Review, we presented case-series where Kampo treatment was introduced for those atopic dermatitis (AD) patients who had failed with conventional therapy, in an attempt to prove that there exists a definite subgroup of AD patients for whom Kampo treatment is effective. In this second part, we will first provide the summary of the results for 140 AD patients we treated in 2000. The results suggest that Kampo treatment is effective for more than half of AD patients who fail with conventional therapy. In the Discussion, we will examine the evidential basis for conventional AD therapy and discuss how Kampo treatment should be integrated into the guidelines for AD therapy. We contend that Kampo treatment should be tried before systematic immunosuppressive agents are considered. As each Kampo treatment is highly individualized, it should be regarded more as ‘art’ than technology, and special care should be taken to assess its efficacy in clinical trial.

show abstract

Atopic dermatitis management: comparing the treatment patterns of dermatologists in Japan, U.S.A. and U.K.

Abstract: Both similarities and differences in the therapy of AD exist in the three countries studied. Factors related to the physician, patient population and culture may influence these observations.

Cited by 25 publications

References 24 publications

Allergies in Asia: differences in prevalence and management compared with Western populations

Allergies in Asia: differences in prevalence and management compared with Western populations

Blood concentrations, tolerability and efficacy of pimecrolimus cream 1% in Japanese infants and children with atopic dermatitis

An Alternative Approach to Atopic Dermatitis: Part II—Summary of Cases and Discussion

Contact Info

Product

Resources

About